Primary Intramedullary Spinal High-Grade Glioma: A Case Series with Review of Literature

Abstract

Aashita

Background Primary intramedullary high-grade glioma (HGG) and glioblastoma of spinal cord are uncommon tumors of central nervous system. Treatment recommendations are based on current guidelines of intracranial HGG and glioblastoma multiforme (GBM).

Methods We retrospectively analyzed records of 9,686 patients who reported to our center over past 7 years. Only three cases of primary intramedullary HGG of spinal cord were found.

Results In this article, we have reported three cases of primary intramedullary HGG of spinal cord. A comparison of intracranial and intramedullary spinal HGG and review of literature is presented.

Conclusion Despite aggressive treatment using surgery, radiation, and chemotherapy, the survival rates are dismal. Emerging evidence has shown difference in biological behavior of intracranial and spinal HGG. Genetic studies to understand the biology and prospective studies are needed.

Keywords

glioblastoma - spinal glioblastoma - spinal astrocytoma - intramedullary glioma - high-grade glioma

Ethical Approval

Taken as applicable in our center. The patients consented for treatment and collection of data.

Consent for Publication

Written informed consent to publish was obtained from individual patients.

Authors' Contributions

A was involved in conceptualization, writing—original draft and editing; RS contributed to conceptualization, editing, and review; VY contributed to editing and supervision; MM and AD edited and reviewed the manuscript; HK, PT, and AM supervised and reviewed the study.

Publikationsverlauf

Artikel online veröffentlicht:
02. Dezember 2022

• References

• 1 Chamberlain MC, Tredway TL. Adult primary intradural spinal cord tumors: a review. Curr Neurol Neurosci Rep 2011; 11 (03) 320-328
• 2 Abd-El-Barr MM, Huang KT, Moses ZB, Iorgulescu JB, Chi JH. Recent advances in intradural spinal tumors. Neuro-oncol 2018; 20 (06) 729-742
• 3 Alvi MA, Ida CM, Paolini MA. et al. Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation. Mod Pathol 2019; 32 (09) 1236-1243
• 4 Liu J, Zheng M, Yang W, Lo SL, Huang J. Impact of surgery and radiation therapy on spinal high-grade gliomas: a population-based study. J Neurooncol 2018; 139 (03) 609-616
• 5 Kandemirli SG, Reddy A, Hitchon P, Saini J, Bathla G. Intramedullary tumours and tumour mimics. Clin Radiol 2020; 75 (11) 876.e17-876.e32
• 6 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131 (06) 803-820
• 7 Nagarajan A, Ravichandar R. Glioblastoma multiforme of spinal cord - case series in a tertiary cancer centre. J Clin Transl Res 2021; 7 (06) 792-796
• 8 Nagaishi M, Nobusawa S, Yokoo H. et al. Genetic mutations in high grade gliomas of the adult spinal cord. Brain Tumor Pathol 2016; 33 (04) 267-269
• 9 Jung JS, Choi YS, Ahn SS, Yi S, Kim SH, Lee SK. Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging. Neuroradiology 2019; 61 (03) 313-322
• 10 Choi SH, Yoon HI, Yi S. et al. Treatment outcomes of radiotherapy for primary spinal cord glioma. Strahlenther Onkol 2019; 195 (02) 164-174
• 11 Kim WH, Yoon SH, Kim CY. et al. Temozolomide for malignant primary spinal cord glioma: an experience of six cases and a literature review. J Neurooncol 2011; 101 (02) 247-254
• 12 Yi S, Choi S, Shin DA. et al. Impact of H3.3 K27M mutation on prognosis and survival of grade IV spinal cord glioma on the basis of new 2016 World Health Organization classification of the central nervous system. Neurosurgery 2019; 84 (05) 1072-1081
• 13 Wang YZ, Zhang YW, Liu WH. et al. Spinal cord diffuse midline gliomas with H3 K27m-Mutant. Neurosurgery 2021; 89 (02) 300-307
• 14 Xie T, Feng Y, Song J, Yao G. Anterior dorsal root entry zone approach in the treatment of spinal intramedullary glioma. World Neurosurg 2021; 153: 139
• 15 Kotecha R, Mehta MP, Chang EL. et al. Updates in the management of intradural spinal cord tumors: a radiation oncology focus. Neuro-oncol 2019; 21 (06) 707-718
• 16 Sahgal A, Chang JH, Ma L. et al. Spinal cord dose tolerance to stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2021; 110 (01) 124-136
• 17 Indelicato DJ, Rotondo RL, Uezono H. et al. Outcomes following proton therapy for pediatric low-grade glioma. Int J Radiat Oncol Biol Phys 2019; 104 (01) 149-156
• 18 Kaley TJ, Mondesire-Crump I, Gavrilovic IT. Temozolomide or bevacizumab for spinal cord high-grade gliomas. J Neurooncol 2012; 109 (02) 385-389
• 19 Majzner RG, Ramakrishna S, Yeom KW. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 2022; 603 (7903): 934-941
• 20 Wolff B, Ng A, Roth D. et al. Pediatric high grade glioma of the spinal cord: results of the HIT-GBM database. J Neurooncol 2012; 107 (01) 139-146
• 21 Miller KD, Ostrom QT, Kruchko C. et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 2021; 71 (05) 381-406
• 22 Grimm SA, Chamberlain MC. Anaplastic astrocytoma. CNS Oncol 2016; 5 (03) 145-157
• 23 Takamiya S, Hatanaka KC, Ishi Y, Seki T, Yamaguchi S. Spinal cord anaplastic astrocytoma with BRAF V600E mutation: a case report and review of literature. Neuropathology 2020; 40 (03) 275-279
• 24 Yao J, Wang L, Ge H, Yin H, Piao Y. Diffuse midline glioma with H3 K27M mutation of the spinal cord: a series of 33 cases. Neuropathology 2021; 41 (03) 183-190